Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
- 24 June 2014
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 32 (48), 6377-6389
- https://doi.org/10.1016/j.vaccine.2014.06.065
Abstract
No abstract availableKeywords
This publication has 128 references indexed in Scilit:
- Nano‐particle vaccination combined with TLR‐7 and ‐9 ligands triggers memory and effector CD8+T‐cell responses in melanoma patientsEuropean Journal of Immunology, 2012
- Anthrax: an updateAsian Pacific Journal of Tropical Biomedicine, 2011
- A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adultsVaccine, 2009
- The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in MaliVaccine, 2009
- Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic CellsImmunity, 2009
- New insights into the regulation of human B-cell differentiationTrends in Immunology, 2009
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervalsVaccine, 2009
- Phenotypic and functional heterogeneity of human memory B cellsSeminars in Immunology, 2008
- Systemic but not mucosal immunity induced by AVA prevents inhalational anthraxMicrobes and Infection, 2007
- Spatiotemporal regulation of MyD88–IRF-7 signalling for robust type-I interferon inductionNature, 2005